NAD referral
This article was originally published in The Tan Sheet
Executive Summary
Advertising for BIE Health Products' GHR "human-growth hormone 'releaser'" has been referred to the Federal Trade Commission and FDA since the firm declined to adequately participate in the National Advertising Division's self-regulatory forum, NAD states July 17. The Council of Better Business Bureaus division identified suspect claims for GHR such as "reversal of many degenerative disease symptoms" and "increased bone density" through its routine and ongoing monitoring program. Although BEI agreed to "provide evidence for review under criteria dictated by BIE," the firm's refusal to participate in NAD's forum according to established procedures leads NAD to refer the ad claims to FTC and FDA for "possible law enforcement action," NAD says...
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.